Sentences with phrase «in ovarian cancer patients»

Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis

[4] Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell - McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S. Phase I trial of overlapping long peptides from a tumor self - antigen and poly - ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study.

A newly devised tumor - specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery, reports Alexander L. Vahrmeijer MD, PhD, head of the Image - guided Surgery group in the Department of Surgery at Leiden University Medical Center in the Netherlands.

Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient.

Not exact matches

In a 564 - person trial, patients whose ovarian cancer recurred (and who had already started treatment with chemotherapy) given Rubraca, part of a new class of cancer drugs called «PARP» inhibitors, lived, on median, for double the amount of time without their disease getting even worse compared with those given a placebo.

Seventy four percent of enrolled patients were diagnosed with ovarian cancer with tumors that had relapsed and metastasized in the peritoneum, the membrane that lines the abdominal cavity.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

Frequent shots of the MIS protein are too expensive for broad use, but they could help protect the reserve of ovarian follicles in young cancer patients.

In order to find out how and why ovarian cancer cells grow and take on such lethal characteristics, Dr. Shepherd and his team grow the cancer cells in 3D structures, called «spheroids» — the same way the cancer cells grow in patientIn order to find out how and why ovarian cancer cells grow and take on such lethal characteristics, Dr. Shepherd and his team grow the cancer cells in 3D structures, called «spheroids» — the same way the cancer cells grow in patientin 3D structures, called «spheroids» — the same way the cancer cells grow in patientin patients.

Closer analysis by independent biostatisticians revealed, however, that the value was calculated on the basis of a single experiment in which half the patients were already known to have ovarian cancer — a highly selected group that is the medical equivalent of a stocked pond.

In order to assess whether an improved diet could reduce the risk of ovarian cancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United StateIn order to assess whether an improved diet could reduce the risk of ovarian cancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Statein African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United SCancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women in 11 sites in the United Statein African - American women in 11 sites in the United Statein 11 sites in the United Statein the United States.

About a quarter of patients had mutations in the DNA repair genes including BRCA1 or BRCA2 genes, which are known to increase the risk of breast and ovarian cancer.

«Personalized tumor vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.»

The study, which compared each model's success in Caucasian women with those of Asian descent (Chinese, Japanese, Filipino, Korean and Vietnamese), also raised important questions about the effect of race on cancer development: When Caucasian and Asian patients with similar family histories of breast and ovarian cancer were compared, the Asian women had higher rates of genetic mutation, although the rates of these cancers for Asians have traditionally been lower.

If these proteins are inactive — which is the case in many patients with breast, ovarian or prostate cancer — the result is a flawed repair.

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

«We know that patients with BRCA mutations are at high risk for developing breast, as well as pancreatic, ovarian, prostate and other cancers, and we have learned over time that BRCA plays a very important role in DNA damage repair.

TRINOVA - 1 was a randomized prospective phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian cancer patient from 179 sites in 32 countries.

Clinical trials of treatments for ovarian and related cancers would benefit from knowledge of patients» gene mutations, but in many trials, the cost of genetic testing is prohibitively expensive, the brief says.

For instance, a plaintiff in the Supreme Court case, Ellen T. Matloff of Yale Cancer Center, said that in 2006 she knew of a patient who had had breast and ovarian cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York Cancer Center, said that in 2006 she knew of a patient who had had breast and ovarian cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York Times.

By evaluating the molecular changes that occur in large cohorts of ovarian cancer patients, the researchers were able to identify several lncRNAs that are linked to the disease.

This high mortality is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80 percent of patients.

Professor Peter Johnson, Cancer Research UK's chief clinician, said: «Although we're making great progress, we still have more to do for people with ovarian cancer, as only one in three patients survive for 10 years or lCancer Research UK's chief clinician, said: «Although we're making great progress, we still have more to do for people with ovarian cancer, as only one in three patients survive for 10 years or lcancer, as only one in three patients survive for 10 years or longer.

Should the results be confirmed by further studies, it is possible that patients with certain genetic changes in BRCA1 could be identified as being at higher risk of breast and ovarian cancer.

In a study of 40 patients with high grade serous ovarian cancer, the researchers monitored tumour DNA that could be detected in a blood sample taken before each chemotherapy treatmenIn a study of 40 patients with high grade serous ovarian cancer, the researchers monitored tumour DNA that could be detected in a blood sample taken before each chemotherapy treatmenin a blood sample taken before each chemotherapy treatment.

This test may be particularly useful for patients with high grade serous ovarian cancer because the mutated cancer gene TP53 is found in more than 99 per cent of patients with this form of the disease.

«In patients with ovarian cancer, we found more pathogenic types of bacteria.»

The research team with international collaborators analysed more than 100 patient samples from ovarian and other cancer types to discover a distinct population of cells found in some tumours.

Studies have shown that ovarian cancer patients have a better chance of survival if they are referred to a specialized gynaecological cancer unit, but this only happens for a minority of women in Europe and the US at present.

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves — despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

The study was done on 10 patients in advanced stages of ovarian cancer.

A section of a tumor organoid grown from cells derived from a patient with high - grade serous ovarian cancer (left) and a mini-tumor treated with ReACp53, resulting in extensive cancer cell death.

«One in five women with ovarian cancer does not undergo surgery, study reveals: Results show survival benefit of surgery for patients regardless of age or advanced disease, and point to barriers to cancer care delivery.»

In some cases such as ovarian cancer, however, drug - free intervals are needed to allow patient recovery from side effects, during which tumors can sometimes begin to grow again or develop resistance to the drugs being used.

In lab experiments, the research team used cell lines derived from 40 patient tumour samples to identify that CD151 contributes to the survival of cells of high - grade serous ovarian cancer origin.

The researchers also are seeking other potential drug targets in the 50 percent of patients who don't have high levels of the anti-death protein, as well as biomarkers in addition to CA125 that could be used to screen for ovarian cancer.

«If studies in larger groups of women confirm our finding that the fallopian tubes are the site of origin of most ovarian cancer, then this could result in a major change in the way we manage this disease for patients at risk.»

«This aligns with what we see in the clinic, that newly - diagnosed ovarian cancer patients most often already have widespread disease,» says Velculescu.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory micIn their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory micin women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratorycancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratorycancer patients treated at the Cancer Institute into laboratoryCancer Institute into laboratory mice.

The results showed that all nine patients lost identical regions of chromosome 17, where the cancer - linked p53 gene is located, in each of the cancer samples, including the early - stage STIC lesions, suggesting that the «misprinted» or flawed p53 gene is an early step in ovarian cancer development.

Next, under the supervision of gynecologist Katja Gaarenstroom, the researchers tested OTL38 in 12 patients with ovarian cancer.

«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10 - 15 % of ovarian cancer patients).

«We are looking forward to further exploring this combination in ovarian cancer and potentially increasing effective treatment options for our patients with this cancer.»

«Niraparib significantly improves outcome of ovarian cancer patients in landmark trial.»

«Phase I study in patients with pancreatic or ovarian cancer.»

The ENGOT - OV16 / NOVA trial evaluated the efficacy and safety of the PARP inhibitor niraparib as maintenance therapy in patients with recurrent ovarian cancer who respond to platinum - based chemotherapy.

It has had particularly strong results in phase III trials in patients who inherited mutations to the BRCA genes, many of whom had breast or ovarian cancer.

Though smaller in number, some patients with advanced disease and carrying a BRCA mutation may benefit from the same targeted therapy being used today in the clinic to successfully treat some ovarian cancer patients.»

But so far in trials for ovarian cancer they have blocked tumor growth in many patients, Levine notes.